Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezacaftor/Ivacaftor in CF (F508del/NR)
NCT02516410Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing VX-661/IVA with Placebo (2 arms). Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second at 12 weeks. Started Aug 2015; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02516410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516410.